Can-Fite BioPharma (CANF) Non-Current Deffered Revenue (2015 - 2025)
Can-Fite BioPharma's (CANF) quarterly Non-Current Deffered Revenue came in at $1.2 million in Q4 2025, down 25.62% YoY from $1.6 million in Q4 2024, and down 14.97% on a QoQ basis from $1.4 million in Q2 2025.
Can-Fite BioPharma (CANF) Non-Current Deffered Revenue (2015 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 11 years of Non-Current Deffered Revenue data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 25.62% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 25.62% YoY) and the FY2025 annual result came in at $1.2 million, down 25.62% from the prior year.
- Non-Current Deffered Revenue fell to $1.2 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $3.6 million in Q1 2021 to a low of $1.2 million in Q4 2025.
- A 5-year average of $2.3 million and a median of $2.2 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 57.52% — and 2023, when it tumbled 30.5%.
- Tracing CANF's Non-Current Deffered Revenue over 5 years: stood at $3.1 million in 2021, then declined by 25.24% to $2.3 million in 2022, then retreated by 25.36% to $1.7 million in 2023, then retreated by 7.71% to $1.6 million in 2024, then fell by 25.62% to $1.2 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $1.2 million (Q4 2025), $1.4 million (Q2 2025), and $1.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.71 Mn |
| Sep 30, 2023 | 1.71 Mn |
| Jun 30, 2023 | 1.90 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 2.66 Mn |
| Mar 31, 2022 | 2.87 Mn |
| Dec 31, 2021 | 3.07 Mn |
| Sep 30, 2021 | 3.09 Mn |
| Jun 30, 2021 | 3.34 Mn |
| Mar 31, 2021 | 3.59 Mn |
| Dec 31, 2020 | 2.16 Mn |
| Jun 30, 2020 | 2.12 Mn |
| Dec 31, 2019 | 2.42 Mn |
| Sep 30, 2019 | 1.57 Mn |